HIF1A and ovarian cancer: Furthermore, using CRISPR/Cas9-mediated HIF-1α gene knockout and co-treatment of CoCl2-simulated hypoxia in ovarian cancer cells, OVCA433 and ES-2, the changes of HIF-1α also did not alter the protein expression level of BCL2A1 (Figure 1E).